Leading GPO Selects MolecuLight i:X Point-of-Care Device as a Key Tool for Informing its National Long-Term Care Membership on the Presence of Elevated Bacterial Burden in Patients' Wounds
VALLEY STREAM, N.Y. and TORONTO, March 9, 2021 /PRNewswire/ -- MolecuLight Inc., the leader in fluorescence imaging for point-of-care detection of wounds containing elevated bacterial loads, announces the availability of its MolecuLight i:X® platform to 650 long-term healthcare facilities in the US through its new commercial arrangement with Synergy HealthCare Alliance, LLC.